RxDoctor Payments Data

Jeffrey Bruning, MD

Family Medicine · la Vista, NENPI 1689056681

Payments from drug & device makers

$7,361in general payments, 2019–2025

Across 330 payments — averaging $22.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$1K
  • AstraZeneca$564
  • GSK$516
  • Amgen$505
  • Bayer$397
  • plus $2K from 32 others

What the payments were for

  • Food & beverage$7,340100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,361 in reported general payments places this provider in the 90th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$163,402
Medicare patients
259
Services billed
7,219

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide75$85,994
JardianceEmpagliflozin60$79,089
FarxigaDapagliflozin Propanediol32$43,805
EliquisApixaban35$34,153
Breztri AerosphereBudesonide/Glycopyr/Formoterol52$31,607
TrulicityDulaglutide20$30,643
OzempicSemaglutide17$28,971
XareltoRivaroxaban20$21,885
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$19,250
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog28$9,822
Dexlansoprazole DrDexlansoprazole16$7,109
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr15$6,973
MyrbetriqMirabegron11$6,920
Advair HfaFluticasone Propion/Salmeterol17$6,254
VascepaIcosapent Ethyl26$4,666

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$168$116,63795 claims
Boehringer IngelheimJardiance$47$79,08960 claims
AstraZenecaFarxiga, Breztri Aerosphere$564$75,41284 claims
PfizerEliquis$172$34,15335 claims
Novo NordiskOzempic$1,219$28,97117 claims
GSKTrelegy Ellipta, Anoro Ellipta$516$26,22344 claims
Johnson & JohnsonXarelto$95$21,88520 claims
Astellas Pharma US IncMyrbetriq$183$6,92011 claims
AbbVieSynthroid$1,939$1,21119 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 981 family medicine providers in Nebraska.

Other family medicine in la Vista

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →